A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

ישראלפעיל (ללא גיוס)PHASE3

מצבים רפואיים

Primary IgA Nephropathy

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona, United States

  • Kaiser Permanente, San Diego, California, United States

  • North America Research Institute, San Dimas, California, United States

  • University of Colorado Anschutz, Aurora, Colorado, United States

  • CaRe Research, Chubbuck, Idaho, United States

  • Nep Assoc of Northern Illinois, Hinsdale, Illinois, United States

  • Johns Hopkins Hospital, Baltimore, Maryland, United States

  • Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

  • Clin Rsrch Consult a JCCT Company, Kansas City, Missouri, United States

  • DaVita Clinical Research, Las Vegas, Nevada, United States

  • New Jersey Kidney Care, Jersey City, New Jersey, United States

  • Col Uni Med Center New York Presby, New York, New York, United States

  • Dallas Renal Group, Dallas, Texas, United States

  • Novartis Investigative Site, Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site, Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, Santa Fe, Argentina

  • Novartis Investigative Site, Woolloongabba, Queensland, Australia

  • Novartis Investigative Site, Adelaide, South Australia, Australia

  • Novartis Investigative Site, Parkville, Victoria, Australia

  • Novartis Investigative Site, Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site, Edegem, Belgium

  • Novartis Investigative Site, Leuven, Belgium

  • Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site, Curitiba, Paraná, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Sao Jose Rio Preto, Brazil

  • Novartis Investigative Site, Temuco, Chile

  • Novartis Investigative Site, Beijing, Beijing Municipality, China

  • Novartis Investigative Site, Beijing, Beijing Municipality, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Luoyang, Henan, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Changsha, Hunan, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Yinchuan, Ningxia, China

  • Novartis Investigative Site, Taiyuan, Shanxi, China

  • Novartis Investigative Site, Xian, Shanxi, China

  • Novartis Investigative Site, Ürümqi, Xinjiang, China

  • Novartis Investigative Site, Ningbo, Zhejiang, China

  • Novartis Investigative Site, Wenzhou, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Guangzhou, China

  • Novartis Investigative Site, Ningbo, China

  • Novartis Investigative Site, Qingdao, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shenzhen, China

  • Novartis Investigative Site, Medellín, Antioquia, Colombia

  • Novartis Investigative Site, Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Aalborg, Denmark

  • Novartis Investigative Site, Aarhus N, Denmark

  • Novartis Investigative Site, Copenhagen, Denmark

  • Novartis Investigative Site, Odense C, Denmark

  • Novartis Investigative Site, Marseille, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Stuttgart, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Aachen, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Hanover, Germany

  • Novartis Investigative Site, Kiel, Germany

  • Novartis Investigative Site, Magdeburg, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, Tübingen, Germany

  • Novartis Investigative Site, Ulm, Germany

  • Novartis Investigative Site, Hong Kong, Hong Kong, Hong Kong

  • Novartis Investigative Site, Pécs, Baranya, Hungary

  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site, Bangalore, Karnataka, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, Hyderabad, Telangana, India

  • Novartis Investigative Site, Ashkelon, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Bologna, BO, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Kasugai, Aichi-ken, Japan

  • Novartis Investigative Site, Toyoake, Aichi-ken, Japan

  • Novartis Investigative Site, Toyota, Aichi-ken, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Kawasaki, Kanagawa, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Kyoto, Kyoto, Japan

  • Novartis Investigative Site, Matsumoto, Nagano, Japan

  • Novartis Investigative Site, Osaka, Osaka, Japan

  • Novartis Investigative Site, Ōmihachiman, Shiga, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Niigata, Japan

  • Novartis Investigative Site, Okayama, Japan

  • Novartis Investigative Site, Osaka, Japan

  • Novartis Investigative Site, Osaka, Japan

  • Novartis Investigative Site, Kuala Lumpur, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Benito Juárez, Mexico City, Mexico

  • Novartis Investigative Site, Querétaro, Mexico

  • Novartis Investigative Site, Groningen, Provincie Groningen, Netherlands

  • Novartis Investigative Site, Nordbyhagen, Oslo, Norway

  • Novartis Investigative Site, Bergen, Norway

  • Novartis Investigative Site, Rostov-on-Don, Russia

  • Novartis Investigative Site, Saint Petersburg, Russia

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Košice, Slovakia

  • Novartis Investigative Site, Ljubljana, Slovenia

  • Novartis Investigative Site, Bloemfontein, Free State, South Africa

  • Novartis Investigative Site, Bundang Gu, Gyeonggi-do, South Korea

  • Novartis Investigative Site, Seoul, Korea, South Korea

  • Novartis Investigative Site, Seoul, Korea, South Korea

  • Novartis Investigative Site, Cheongju-si, North Chungcheong, South Korea

  • Novartis Investigative Site, Seoul, Seoul, South Korea

  • Novartis Investigative Site, Busan, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Taegu, South Korea

  • Novartis Investigative Site, Pamplona, Navarre, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Stockholm, Sweden

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, New Taipei City, Taiwan

  • Novartis Investigative Site, New Taipei City, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site, Köseköy, Kocaeli, Turkey (Türkiye)

  • Novartis Investigative Site, Antalya, Konyaalti, Turkey (Türkiye)

  • Novartis Investigative Site, Kayseri, Melikgazi, Turkey (Türkiye)

  • Novartis Investigative Site, Istanbul, Sariyer, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

  • Novartis Investigative Site, Mersin, Yenisehir, Turkey (Türkiye)

  • Novartis Investigative Site, Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Novartis Investigative Site, Cambridge, United Kingdom

  • Novartis Investigative Site, Leicester, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Salford, United Kingdom

  • Novartis Investigative Site, Ho Chi Minh City, VNM, Vietnam

  • Novartis Investigative Site, Ho Chi Minh City, Vietnam

מובילי המחקר
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals